Literature DB >> 137413

Erythrocyte membrane cation carrier in mania.

G J Naylor, D A Dick, E G Dick, E P Worrall, M Peet, P Dick, L J Boardman.   

Abstract

Erythrocyte sodium and potassium concentrations, erythrocyte membrane ATPase (Na-K specific and non-specific) and the rate of potassium influx into erythrocytes (ouabain-sensitive and insensitive) were estimated in a group of female patients suffering from mania and repeated on about two thirds of them when they had recovered. With recovery there was a statistically significant increase in the erythrocyte ouabain-sensitive potassium influx. The other parameters showed no significant overall change with recovery but the initial severity correlated significantly and negatively with the change in erythrocyte Na-K ATPase with recovery. The changes that occurred in the erythorcyte sodium concentration and Na-K ATPase activity were not random since they correlated significantly with changes in the active potassium influx.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 137413     DOI: 10.1017/s0033291700018316

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  3 in total

1.  The effect of oral salbutamol on cation transport measured in vivo in healthy volunteers.

Authors:  A J Wood; C J Brearley; J K Aronson; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

2.  A study of the transport of lithium across the erythrocyte membrane in vivo and of the effects of the ion transport inhibitors digoxin and dipyridamole.

Authors:  A J Wood; J K Aronson; C Bunch; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

3.  The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [3H]-ouabain binding to human lymphocytes after incubation for 3 days.

Authors:  W G Rapeport; J K Aronson; D G Grahame-Smith; C Harper
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.